UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

With Two Late-Stage Candidates

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

Grand Place, Brussels
Brussels, Where UCB is headquartered • Source: Shutterstock

More from Clinical Trials

More from R&D